Stephen Mollichella, currently the company’s senior vice president and controller, will assume the role of interim principal financial officer. Mollichella brings over twenty years of industry experience to the position, having established Harmony’s internal accounting infrastructure since joining the organization in 2021.
In section Market Quotes
Harmony Biosciences CFO Resigns Amidst Revenue Growth
Glenn Reicin is stepping down as Chief Financial Officer of Harmony Biosciences effective Thursday, leaving the pharmaceutical company to pursue new career opportunities. The announcement arrives as the firm reports a significant surge in quarterly product revenue for its flagship sleep disorder medication, Wakix, despite a lingering decline in share price.
Preliminary figures indicate that net product revenue for Wakix reached $261 million for the second quarter, marking a 30% increase compared to the previous year. Chief Executive Jeffrey Dayno attributed these results to the sustained commercial momentum of the Wakix franchise. Despite this growth, Harmony stock fell 4.5% to $33.35 following the news, extending a year-to-date slide of nearly 11%. The company plans to release comprehensive financial results during an investor update scheduled for August 4.
Comments (0)
No comments yet. Be the first!